China NMPA Product Recall - Ogival Interbody interbody fusion device

Stryker Spine Corporation, through its Beijing subsidiary Stryker (Beijing) Medical Devices Co., Ltd., has initiated a voluntary Class III recall of its Ogival Interbody Fusion Device (National Medical Device Registration Certificate 20163131310). This action, publicized by the National Medical Products Administration (NMPA) on June 1, 2023, stems from an identified manufacturing issue: incorrect height markings on the interbody fusion devices. The recall is categorized as Class III, indicating that while the defect is not expected to cause serious adverse health consequences, it represents a deviation from product specifications that warrants corrective action. The NMPA's involvement underscores its role in overseeing medical device safety and ensuring manufacturers adhere to established quality and regulatory standards within China. Stryker's proactive recall demonstrates compliance with the regulatory framework governing medical devices, ensuring patient safety and product integrity. The company is required to provide detailed information on affected models, specifications, and batch numbers in an official recall report form, accessible through the NMPA's official channels.